Applying quantitative proteomics to tumor marker discovery
With tumor therapy becoming increasingly a focus of researchers and investors alike, the demand for effective tumor markers grows strongly. Entelechon has started an initiative for the development of tumor marker discovery kits. The project is funded by the German BMBF (Ministry of Education and Research) and aims at the design of a combined depletion and enrichment kit specific to a panel of potential tumor markers.
Tumor diagnostics is hampered by the extremely low abundance of tumor markers in blood serum. Techniques for detecting such markers must therefore be fine-tuned to reach a very high level of sensitivity. In the project, Entelechon will develop a kit which allows to deplete abundant proteins, such as immunoglobulines or albumin, in a serum sample, and to specifically enrich target marker proteins.
A consortium of four partners: The Institute for Pathology and the Surgical Clinic of the University Medical Center Erlangen, the Biobank of the University Cancer Center Erlangen, the Institute for Biochemistry of the Friedrich-Alexander-University Erlangen-Nürnberg, and Entelechon. The Institute for Biochemistry will contribute mass spectrometry expertise and the development of analytical protocols, while the clinical partners will contribute expertise on tumor markers, as well as serum samples of healthy subjects and patients.
With this project, Entelechon continues its successful activities in the field of tumor diagnostics, which had started with the participation in the DECanBio consortium. DECanBio aims at identifying biomarkers for bladder cancer in urine.
The project will provide new approaches and answers for R&D laboratories and pharma companies working on the validation of biomarkers for drug development. The kit will also be a foundation for other products for the parallel detection of multiple biomarkers in cancer and other diseases.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Last viewed contents
Novel insights in MET-proto-oncogene might lead to optimizing cancer treatment - MET inhibitors could have a double-edged effect on tumors
Mosaiques and U.S. FDA sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity
Danny_Glover
LEUKOCARE has been granted both ISO 9001 and ISO 13485 certification
Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics
Seegene Receives Approval from Health Canada for Its Respiratory Virus Multi-Pathogen Detection Tests
MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
